Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Molecular Partners AG maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions. These actions are spread across 3 distinct art units, indicating a diverse range of technical subject matter within the biotechnology sector. Prosecution involves 3 distinct examiners, one for each pending matter.
BERHANE, SELAM is the busiest examiner for the portfolio, currently managing 1 busiest examiner pending action. Because there are 3 distinct examiners and 3 distinct art units, practitioners must be prepared for a decentralized prosecution process. Each of the 3 pending office actions is being handled by a different individual in a different art unit, which may result in varied timelines and requirements. Success in the Biotechnology & Pharmaceuticals area for this portfolio will depend on addressing the unique perspectives of BERHANE, SELAM and the other examiners involved. The presence of 1 busiest examiner pending action under BERHANE, SELAM represents one component of the total pending workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERHANE, SELAM | 1 | 59.1% | +56.4% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| BOESEN, CHRISTIAN C | 1 | 76.0% | +21.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174086 | RECOMBINANT PEPTIDE-MHC COMPLEX BINDING PROTEINS AND THEIR GENERATION AND USE | BOESEN, CHRISTIAN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18281161 | NOVEL DARPIN BASED CD123 ENGAGERS | BERHANE, SELAM | — |
| 18267608 | RECOMBINANT CD3 BINDING PROTEINS AND THEIR USE | BRADLEY, CHRISTINA | — |
| 18174086 | RECOMBINANT PEPTIDE-MHC COMPLEX BINDING PROTEINS AND THEIR GENERATION AND USE | BOESEN, CHRISTIAN C | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1654 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18281161 | NOVEL DARPIN BASED CD123 ENGAGERS | BERHANE, SELAM | 1675 | §112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18267608 | RECOMBINANT CD3 BINDING PROTEINS AND THEIR USE | BRADLEY, CHRISTINA | 1654 | §102§112DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18174086 | RECOMBINANT PEPTIDE-MHC COMPLEX BINDING PROTEINS AND THEIR GENERATION AND USE | BOESEN, CHRISTIAN C | 1684 | §102§112 | Non-Final OA | — | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMolecular Partners AG has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Selam Berhane has the most, with 1 of Molecular Partners AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
